



PARABOLIC DRUGS LIMITED

Parabolic Drugs' H1 FY12 sales up 39.49% to Rs 420.66 crore Net Profit up 19.12% to Rs. 29.57 Crore

H1 FY12 Results Media Release

BSE Code: 533211
NSE Code: PARABDRUGS

FY11 Sales: Rs. 675.30 crore
5 year CAGR: 41.84%
FY11 Net Profit: Rs. 52.87 crore
5 year CAGR: 39.71%

Headquartered in Chandigarh, with three manufacturing facilities – two in Punjab and one in Haryana; a world-class custom synthesis and R&D centre at Barwala, (Haryana)

1200+ employees including R&D Team of 100 Scientists

Product portfolio comprising of 44 APIs and 7 API intermediates; filed 38 Drug Master Files

Aiming to emerge as a Global Pharmaceuticals Company by 2015

For more information:

Sameer Madan
Vice President- Trade Finance
Parabolic Drugs, Chandigarh
sameer.madan@parabolicdrugs.com
+ 91 172 391 4658

Parthajeet Sarmah
Christensen
psarmah@christensenir.com
+91 98670 01356

Chandigarh, November 12, 2011: Parabolic Drugs Ltd., a vertically integrated API manufacturer and exporter in India, today announced the unaudited results for quarter ended September 30th, 2011.

Q2FY12 Performance

- The Company's sales increased by 33.30% to Rs. 215.19 crore as compared to Rs. 161.43 crore in Q2 FY 11
- Net profit at Rs. 14.38 crore as compared to Rs. 14.29 crore in Q2 FY 11
- EBITDA increased by 43.35% to Rs. 42.58 crore as compared to Rs. 29.70 Crore in Q2 FY 11
- The company's EBIDTA margin was up 154 basis points to 21.77%
- The company's net profit margin stood at 7.35% in Q2 FY12

H1FY12 Performance

- Sales increased by 39.49% to Rs. 420.66 crore during H1FY12 as compared to Rs. 301.58 crore in H1FY11
- Net profit up 19.12% at Rs. 29.57 crore as compared to Rs. 24.82 crore in H1FY11
- EBITDA increased by 52.20% to Rs. 84.38 crore in H1FY12
- The company's EBIDTA margin was up 189 basis points to 22.10%
- The company's net profit margin stood at 7.74% in H1FY12

Major operational highlights for H1 FY 12

During the first half of FY 12, the company received an official accreditation from Japan's Ministry of health, labour and Welfare designating it as a Certified Foreign Drugs Manufacturer for Cephalosporin Oral supplies to Japan which is world's second largest drugs market. The impact of inflationary pressures across the economy has resulted in frequent interest hike by RBI. This had a undesirable impact on the profitability for the Q2. The company also filed its first DMF in Japan. This is company's 38th Regulatory filing and first in Japanese market. In the capacity additions, the company successfully accomplished the capacity expansion of its Amorphous production at Derabassi with the commissioning of eighth plant. Amongst the other strategic areas, there have been significant developments in the formulations space and CRAMS operations. The company has also filed its seventeenth patent application to Indian Patents office for a molecule in the Anti-diabetic therapy. In line with the diversified and global growth approach, PDL has advanced its market presence in some new countries chiefly in APAC, Africa and Latin America.



PARABOLIC DRUGS LIMITED

Management comment

Commenting on the performance, Mr. Vineet Gupta, Director, Parabolic Drugs, said, “We have had a strong first six months for FY 12 and we believe that the building blocks put in place would lay a strong foundation for strategic growth of the company. With the Japanese Accreditation and filing of our first drug master file in Japan, we are hopeful of tapping marquee customers and business in the Japanese market which by far is one of the most stringent regulated pharmaceutical markets. Going forward, with the commencement of regulatory filings and IPR development for non-antibiotics, we are likely to observe significant developments in new therapies and segments.”

About Parabolic Drugs Ltd.

Parabolic Drugs Ltd., incorporated in 1996, is promoted by professionally qualified first generation entrepreneurs. It is engaged in manufacturing, including contract manufacturing, of APIs and API intermediates for domestic and international markets, including regulated markets. It manufactures Semi Synthetic Penicillin (“SSP”) and Cephalosporin range of antibiotics, whereby the product portfolio comprises 44 APIs and 7 API intermediates. The company has two manufacturing facilities located at Derabassi, Punjab and Panchkula, Haryana. It also has a custom synthesis and R&D centre at Barwala, Haryana, which started operations in January 2010. Proposed facilities include a manufacturing facility for non-antibiotic products at Chachrauli, Derabassi and another custom synthesis and manufacturing site at Panchkula being set up by PDL’s subsidiary.